# Parallel Phase I/II Trial of Decitabine and Peg-Interferon in Melanoma: Phase I Portion

> **NCT00791271** · PHASE1 · TERMINATED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 17 (actual)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** Decitabine
- **DRUG:** Pegylated Interferon Alpha-2b

## Key facts

- **NCT ID:** NCT00791271
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-09-02
- **Primary completion:** 2015-05
- **Final completion:** 2015-05
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2018-11-09

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00791271

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00791271, "Parallel Phase I/II Trial of Decitabine and Peg-Interferon in Melanoma: Phase I Portion". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00791271. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*